不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: a clinicopathological study of 15 cases.
Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: a clinicopathological study of 15 cases.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
淋巴增殖性疾病(LPD)可发生于炎症性肠病(IBD)患者,如溃疡性结肠炎(UC)和克罗恩病(CD)。在极少数情况下,IBD患者会发生髓系肿瘤;然而,日本患者中IBD相关淋巴和髓系增殖性疾病(LMPD)的发生频率及临床病理特征仍不清楚。
在本研究中,我们回顾了2474例日本IBD患者,发现LMPD发生于12例(0.5%)UC(n = 7)或CD(n = 5)患者。连同另外3例,我们共分析了15例LMPD的临床病理和组织学特征。根据是否使用生物制剂和免疫调节剂等免疫抑制剂、Epstein-Barr病毒(EBV)感染状态以及组织病理学,将15例分为I组(高级别LPD;n = 7)、II组(低级别LPD;n = 5)和III组(髓系肿瘤;n = 3)。I组大多数患者正在接受强效免疫抑制治疗,其LPD病变对应于高级别B细胞或T细胞/NK 细胞淋巴瘤,常伴有EBV感染。仅停用免疫抑制药物并不能使这些LPD缓解;I组患者需要化疗,最终其中4例(57%)死于肿瘤。II组大多数病例为不伴EBV感染的低级别B细胞淋巴瘤,临床病程惰性,预后极佳。III组所有患者均在CD病程中发生急性髓系白血病(AML)。其中2例(67%)死于AML。
我们的研究表明,IBD相关LMPD非常罕见,但可呈侵袭性临床病程。
Lymphoproliferative disorder (LPD) can occur in patients with inflammatory bowel disease (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). On rare occasions, patients with IBD develop myeloid neoplasms; however, the frequency and clinicopathological features of IBD-associated lymphoid and myeloid proliferative disorder (LMPD) in Japanese patients are still unclear. In this study, we reviewed 2474 Japanese patients with IBD and found that LMPD occurred in 12 (0. 5%) patients with UC (n = 7) or CD (n = 5).
Together with an additional 3 cases, we analyzed a total of 15 cases of LMPD for clinicopathological and histological features. Based on the status of using immunosuppressants such as biologics and immunomodulators, Epstein-Barr virus (EBV) infection, and histopathology, the 15 cases were classified into Group I (high-grade LPD; n = 7), Group II (low-grade LPD; n = 5), and Group III (myeloid neoplasms; n = 3). Most patients in Group I were undergoing strong immunosuppressive therapy, and the LPD lesions corresponded to high-grade B-cell or T cell/natural killer cell lymphoma often with EBV infection.
Discontinuation of immunosuppressive drugs alone did not resolve these LPDs; Group I patients required chemotherapy, and eventually 4 of them (57%) died of the tumor. Most cases in Group II were low-grade B-cell lymphoma without EBV infection and had an indolent clinical course with excellent prognosis. All patients in Group III developed acute myeloid leukemia (AML) during the course of CD. Two (67%) of these patients died of AML.
Our study suggests that IBD-associated LMPD is very rare but can follow an aggressive clinical course.
MEMBER ACCOUNT
登录成功会直接打开下一页。